Observe Medical Valuation
Is OM5A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OM5A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OM5A's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OM5A's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OM5A?
Key metric: As OM5A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is OM5A's PS Ratio? | |
|---|---|
| PS Ratio | 2.9x |
| Sales | NOK 29.18m |
| Market Cap | NOK 83.53m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.7x |
| Enterprise Value/EBITDA | -4.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OM5A's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.6x | ||
AUG Audientes | 12.6x | n/a | €6.9m |
GME Geratherm Medical | 0.8x | 1.9% | €15.0m |
MF6 MagForce | 3.3x | 50.9% | €3.6m |
AAQ1 aap Implantate | 1.9x | n/a | €22.4m |
OM5A Observe Medical | 3.1x | n/a | €89.4m |
Price-To-Sales vs Peers: OM5A is expensive based on its Price-To-Sales Ratio (3.1x) compared to the peer average (1.3x).
Price to Sales Ratio vs Industry
How does OM5A's PS Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: OM5A is good value based on its Price-To-Sales Ratio (3.1x) compared to the European Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is OM5A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate OM5A's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.18
7D
-2.7%
1Y
6.1%
Shandong Weigao Group Medical Polymer
HK$20.7b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.54
7D
-1.8%
1Y
-37.1%
LNA Santé
€242.3m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.8%
1Y
15.7%